Kristof C.
- Country
- Belgium
- Department
- Pneumonology
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- Investigation of EOS301984 in Adult Patients with Advanced Solid Tumors
- Efficacy of Cobolimab, Dostarlimab, and Docetaxel in Advanced Non-Small Cell Lung Cancer Post Anti-PD(L)1 Therapy and Chemotherapy
Data & Insights
Has run more than one trial at 484 of 728 partner sites.
Specializations
Non-Small Cell Lung Cancer Treatment
This investigator specializes in studying advanced therapeutic approaches for non-small cell lung cancer (NSCLC), with particular focus on locally advanced and metastatic disease states. Their research encompasses novel treatment combinations involving immunotherapy and targeted therapies.
- First-line treatment strategies
- Combination therapy approaches
- Advanced stage disease management
Molecular and Biomarker Research
The investigator focuses on precision medicine approaches targeting specific genetic mutations and biomarkers in lung cancer. Their work includes studies on EGFR mutations, HER2 mutations, KRAS G12C alterations, and MET overexpression.
- Targeted therapy development
- Biomarker-driven treatment selection
- Resistance mechanism studies
Small Cell Lung Cancer Research
The investigator conducts research in limited-stage small cell lung cancer (LS-SCLC), particularly focusing on consolidation therapy approaches following chemoradiotherapy. Their work includes evaluation of novel immunotherapy combinations.
- Post-chemoradiation treatment strategies
- Immunotherapy combinations
- Disease progression assessment
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.